To determine the biologic significance of the structural rearrangements of the long arm of chromosome 6(6q) in acute lymphoblastic leukemia (ALL) at diagnosis, we studied 412 consecutive children whose leukemic cell chromosomes had been completely banded and identified 45 (1 1 %) children with this abnormality. The 45 cases were divided into del(6q) only (n = 11 1, del(6q) and numerical abnormalities (n = 41, del(6q) and structural abnormalities (n = 23). and 6q translocations (n = 7). The breakpoints of del(6q) were subgrouped: del(6)(ql5q21) in 11 cases, del(6) (q13q21) in six, de1(6)(q21 q23) in four, del(6)(ql5) in four, de1(6)(q15q23) in three, and other deletions in 10 cases. Notably, all these deletions encompassed the 6q21 band, suggesting that this might be the locus of a recessive tumor suppressor gene, the absence of which contributes t o malignant transformation or proliferation. Among the seven children with 6q translocations, a previously unidentified nonrandom translocation, t(6;12)(q21 ;PI 3) was noted ECENT MOLECULAR genetic analyses of retinoblas-R toma (Rb) and Wilms tumor (WT) have focused on recessive tumor suppressor genes.'-4 Similar mechanisms have been implicated in the pathogenesis of other tumor^.^.^ Although these mechanisms have not been well documented in hematological malignancies, the high frequency of specific chromosome loss or deletion suggests that these genetic mechanisms may be important in the pathogenesis of these disorder^.^ Several nonrandom chromosome abnormalities have been specifically associated with acute lymphoblastic leukemia (ALL).7-9 Deletion of the long arm of chromosome 6 [del(6q)] is a common chromosomal abnormality in but its clinical and biologic significance has not been defined. Previous studies have disclosed a del(6q) abnormality in 4% to 13% of in 17% to 23% of non-Hodgkin lymphomas (NHL),I4,l5 and less frequently in acute nonlymphocytic leukemias (ANLL)7.16 and chronic myelogenous leukemias Clinical features and event-free survival were similar among children with or without 6q abnormalities. Overall, children with 6q abnormalities were less likely than those without the abnormality t o have a pre-B immunophenotype ( P = .03). T-cell immunophenotypes were equally represented in cases with or without 6q abnormalities. However, all four children with del(6q) and a 12p abnormality had early pre-6 ALL and all three children with del(6q) and a 9p abnormality had a T-cell immunophenotype. The lack of specificity for a particular immunophenotype may imply that the gene or genes affected by 6q abnormalities are broadly active in the multistep process of lymphoid leukemogenesis. The relatively high frequency of microscopically visible del(6q) indicates the need for molecular studies t o identify cases with submicroscopic deletions.
To determine the biologic significance of the structural rearrangements of the long arm of chromosome 6(6q) in acute lymphoblastic leukemia (ALL) at diagnosis, we studied 412 consecutive children whose leukemic cell chromosomes had been completely banded and identified 45 (1 1 %) children with this abnormality. The 45 cases were divided into del(6q) only (n = 11 1, del(6q) and numerical abnormalities (n = 41, del(6q) and structural abnormalities (n = 23). and 6q translocations (n = 7). The breakpoints of del(6q) were subgrouped: del(6)(ql5q21) in 11 cases, del(6) (q13q21) in six, de1(6)(q21 q23) in four, del(6)(ql5) in four, de1(6)(q15q23) in three, and other deletions in 10 cases. Notably, all these deletions encompassed the 6q21 band, suggesting that this might be the locus of a recessive tumor suppressor gene, the absence of which contributes t o malignant transformation or proliferation. Among the seven children with 6q translocations, a previously unidentified nonrandom translocation, t(6;12)(q21 ;PI 3) was noted ECENT MOLECULAR genetic analyses of retinoblas-R toma (Rb) and Wilms tumor (WT) have focused on recessive tumor suppressor genes.'-4 Similar mechanisms have been implicated in the pathogenesis of other tumor^.^.^ Although these mechanisms have not been well documented in hematological malignancies, the high frequency of specific chromosome loss or deletion suggests that these genetic mechanisms may be important in the pathogenesis of these disorder^.^ Several nonrandom chromosome abnormalities have been specifically associated with acute lymphoblastic leukemia (ALL).7-9 Deletion of the long arm of chromosome 6 [del(6q)] is a common chromosomal abnormality in but its clinical and biologic significance has not been defined. Previous studies have disclosed a del(6q) abnormality in 4% to 13% of in 17% to 23% of non-Hodgkin lymphomas (NHL),I4,l5 and less frequently in acute nonlymphocytic leukemias (ANLL)7.16 and chronic myelogenous leukemias in two cases with an early pre-6 immunophenotype. Clinical features and event-free survival were similar among children with or without 6q abnormalities. Overall, children with 6q abnormalities were less likely than those without the abnormality t o have a pre-B immunophenotype ( P = .03). T-cell immunophenotypes were equally represented in cases with or without 6q abnormalities. However, all four children with del(6q) and a 12p abnormality had early pre-6 ALL and all three children with del(6q) and a 9p abnormality had a T-cell immunophenotype. The lack of specificity for a particular immunophenotype may imply that the gene or genes affected by 6q abnormalities are broadly active in the multistep process of lymphoid leukemogenesis. The relatively high frequency of microscopically visible del(6q) indicates the need for molecular studies t o identify cases with submicroscopic deletions. 0 1990 by The American Society of Hematology.
(CML).' This abnormality has been associated with T-cell and adult T-cell l e~k e m i a . '~. '~ To determine the frequency and clinical significance of 6q abnormalities, we studied a large cohort of children with ALL whose leukemic cells were successfully karyotyped.
MATERIALS AND METHODS
From January 1983 to April 1988, we analyzed complete karyotypes of leukemic cells from 412 of 544 children with newly diagnosed ALL. These patients were the subjects of two St Jude total therapy studies (X and XI)20-22 that used different treatment regimens based on the patients' initial risk features and subsequent randomization. Informed consent was obtained from the patients or their guardians, and the investigation was approved by the institution's clinical trials review committee.
Bone marrow smears were stained with Wright-Giemsa, periodic acid-Schiff, myeloperoxidase, Sudan black B, and a-naphthyl butyrate esterase. The diagnosis of ALL was based on examination of Wright-stained smears of bone marrow aspirates classified according to the FrenchAmerican-British (FAB) morphological criteriaz3 and negative myeloperoxidase and a-naphthyl butyrate esterase staining.
Bone marrow samples were processed according to the method of Williams et a124; additional 24-hour cultures were also performed when samples were available. G-Banding was performed by treatment with trypsin and staining with Wright stain. When more than one cell line was observed, the stemline was defined as the most frequent cell line and chromosome abnormalities were classified according to the International System for Human Cytogenetic Nomenclature ( 1985) .25
Cell-surface antigens were detected by a standard indirect immunofluorescence assay with monoclonal antibodies (MoAbs) to lymphoid-associated antigens, including 55 (common ALL antigen, CALLA, CDlO), T11 or Leu5 (CD2), T1 or Leu1 (CDS), T3 or Leu4 (CD3), B1 (CD20) and B4 (CD19), as well as myeloid-associated antigens including MY 1 (CDl5), MY4 (CD14), MY7 (CD13), MY9 (CD33), and 5F1 (CD36). Blast cells were also tested for surface (sIg) and cytoplasmic immunoglobulin (cIg). Terminal deoxynucleotidyl transferase (TdT) was detected by an immunofluorescence assay. On the basis of their pattern of Morphological and cytochemical studies.
Chromosome analysis.
Immunophenotyping.
6a ABNORMALITIES IN ALL 1627 reactivity, lymphoblasts were classified as T (CD5+, CD7+, whether or not they were E rosette positive), B (sIg+), pre-B (cIg+), or early pre-B (CD19+, CD5-, CD7-, cIg-, sIg-, and CDlO') as previously descri bed. 26 Probing of high-molecular-weight DNA was performed as described previously.27,28 BamHI, EcoRI, and Hind111 digestions were used for analyzing Ig heavy-chain (IgH) genes; the probe consisted of a 3.4-kilobase (kb) EcoRIIHindIII fragment of the joining region (JH). BamHI digestions were also probed by using a 2.5-kb K light-chain gene fragment. T-cell receptor @-chain (TCR-@) gene rearrangements were analyzed after BamHI, EcoRI, or XbaI digestion by probing with pB400, a 0.4-kb cDNA-containing sequence for C@,. DNAs were labeled by the oligolabeling procedure. The filters were exposed to Kodak XAR Southern blot analysis. + 2 1, +2 1, +22. +22, +2de1(6) (ql5) (q2 l),de1(9) (p12-~13)/46,XX,de1(61(q15q2 1 ),de1(9) (pl2-pl3) 56,XX,+?,dup(l)(q24-q42),de1(6) (q13q21) 46,XY,-7,-12,+dic(7; 12) ( p l l;pl2),del(6)(ql4q23).+mar/45,XY,-7,-12,+dic(7;12),de1(6) 46.XX.deN9) (p22), -9, +der(9)t(9;?) (q34;?)/46,XX,same,de1(6) (41 5q21) 46.XY.deN6) (42 lq23). - 46,XY,t(3; 12) (q12;~12).de1(6) (41 5)/46,XY,de1(6) 46,XY,t(1;4) (q44;q21),de1(6)(q15),-9,+der(9)t(9;?) (~23;)) 45,X,-X,t~l;3)~p34;p21),de1~6)~q13q21) 46,XX,de1(6) (ql5q22),i(9q),del( 13) (42 l),t( 1; 19) (q23;~13)/46,XX,same.t(2; 14) (p 13;q32) 45.X. -XJ( 1;3) (q42;q28).de1(6) (41 5q23),del(13) (ql2q14) 46,XX. -7, +der(7)t(7;?) (p22;?),del( 18) (ql2),t(10; 1 1) (p14-p 15;q22-q23)/47,XX,same, +de1 (6) 10,-1 ,+der(l)t(l;?) (p36;?),-6,+der(6)t(6;?) (q27;?),-7,+der(7)t(7;?) (q36;?), T -13,+dar(13)t(9;13)(ql l;p12),-16,+der (16) 
RESULTS
Thirty-five (8.5%) of the 412 children with successful studies had normal chromosomes, and 45 (1 1%) had 6q abnormalities: del(6q) only (n = 11); del(6q) and numerical abnormalities (n = 4); del(6q) and structural abnormalities (n = 23); and 6q translocations (n = 7) ( Table 1 ). The 6q deletion breakpoints were subgrouped as: de1(6)(q15q21) (n = 11). de1(6)(q13q21) (n = 6), de1(6)(q21q23) (n = 4). de1(6)(q15) (n = 4). del(6)(ql5q23) (n = 3). and various other 6q deletion breakpoints (n = 10). Deletions in all these 38 cases involved the 6q21 band. A schematic representation of the extent of 6q deletions is shown in Fig 1: The deleted region was between 6q13 and 6q21 in nine of 11 cases with del(6q) as the sole abnormality, whereas the deleted region involved distal 6q (6q23 -ter) in 9 of 23 children with structural abnormalities.
Among the seven children with 6q translocations, two children with early pre-B ALL had the same newly identified translocation, t(6;12)(q21;p13), one child with T-cell ALL had a t(6;7)(q24;q36), and one child with early pre-B-ALL had a t(2;6)(p21;q15). The remaining two children had unbalanced translocations. Only one child (case 39) had an unbalanced chromosomal translocation resulting in monosomy of a fragment of chromosome 6qter. 9 translocations involved 6q 15 in two cases, 6q2 1 in two cases, and other bands in three cases. Additional complex abnormalities were noted in cells from most children who had a 6q translocation.
Twenty-six (58%) of the 45 cases were pseudodiploid, four (9%) were hypodiploid, eight (18%) were hyperdiploid 47 to 50, six (13%) were hyperdiploid >50, and one (2%) was near-tetraploid. More than two related cell lines were observed in 18 cases. Numerical abnormalities consisted of trisomy or tetrasomy of chromosome 21 in nine cases, + 18 in four, and + 6, + 14, + 16 in three cases each.
None of the children in this study had either the t(9;22) or 1 lq23 translocations. The nonrandom translocation, t( 1 ;19), in addition to del(6q), was identified in one child. Additional chromosomal deletions including unbalanced translocations resulting in monosomy of a part of the chromosome were present in 16 cases: 12p-in four, 9p-in three, 7q-in two, and 8p-, 9q-, 1Oq-, 13q-, 18q-, and Xq-in one case each. Each of the four cases (18, 19, 23 , and 27) with rearrangement involving the 1 2~1 2 region had an early pre-B-cell immunophenotype, and the three cases with rearrangements involving 9p had T-cell immunophenotype.
Immunophenotyping and genotyping. Immunophenotype results for the 45 children with 6q abnormalities are shown in Table 2 . Children with 6q abnormalities were significantly less likely to have pre-B-ALL as compared with those without the chromosomal changes: 4 of 44 cases v 93 of 347 children tested (P = .03). Moreover, none of the children with 6q abnormalities in this study had mixed-lineage expression or a CALLA-early pre-B-cell immunophenotype. In children with 6q abnormalities, IgH gene and TCR-j3 gene rearrangements were noted in 17 of 21 and 1 1 of 18 children, respectively. Clinical and laboratory data and treatment outcome. Initial clinical and laboratory features of ALL children (age, sex, race, hemoglobin, white blood cell and platelet count, liver and spleen size, and C N S involvement) were similar for the 45 children with 6q abnormalities and the other 367 children lacking this abnormality (data not shown). None of the children with 6q abnormalities were infants. There were no differences in remission induction rates or event-free survival of ALL children for the groups with or without any 6q abnormality (P = .98).
DISCUSSION
Chromosomal abnormalities involving the 6q region were identified in 11% of children with ALL in this study. In our experience, the frequency of 6q abnormalities in childhood ALL is similar to that of 12p abnormalities (10%)" or 9p abnormalities (lo%).'* Although 6q abnormalities are observed in childhood ANLL, we have noted a very low frequency (0.9%).16 A nonrandom translocation, t(6; 12)(q21; p13) was newly identified in two children who had an early pre-B immunophenotype. Of interest is the finding of +21 in eight children, an abnormality that occurs often in hyperdiploid >50 ALL. ' The precise breakpoint of del(6q) in ALL has not been determined because the chromosomes are fuzzy and short, and the banding pattern is indistinct; thus, the reported breakpoints of del(6q) have varied from q15 to q24.9-13*17 The deletions of chromosome 6 in all 38 cases we examined involved the q21 band. Our results suggest that a tumorsuppressor gene may be located in this region, whose absence through deletion may contribute to malignant transformation or proliferation.
Oshimura et all0 first reported that the del(6q) in ALL was associated with a T-cell immunophenotype; this abnormality also occurs frequently in adult T-cell 1 e~k e m i a . I~~'~ Although 6q abnormalities are present in some childhood ALLs with a T-cell immunophenotype, we and other researchers have found 6q abnormalities to be equally prevalent in B-lineage ALL.8.9,' 1-1 3. 1 7 Te n of the 45 children with 6q abnormalities had T-cell immunophenotype, as did 62 of 367 children without this abnormality (P = .35). TCR-P gene rearrangement was noted in 11 of 18 children examined, although a high frequency of these rearrangements has also been associated with nowT-cell ALL.27.28
A pre-B-cell immunophenotype and myeloid-antigen expression were observed less frequently in children with 6q abnormalities as compared with children lacking 6q abnormalities. Notably, all four children with concurrent del( 12p) had an early pre-B-cell immunophenotype as was previously r e p~r t e d .~' All three children with concurrent del(9p) had T-cell immunophenotype, an association that has been noted by other r e s e a r c h e r~~~~~~ but is c o n t r~v e r s i a l .~~ The karyotype of patient 24 had a stem line with del(9p) and a side line with del(9p) and del(6q). These findings suggest that 6q loss may develop later in a multistep process of malignant transformation, as previously suggested by Vogelstein et a16 for colon cancer. Nonetheless, 11 children with del(6q) as the sole abnormality were identified in our study.
Patients with del(6q) were reported to have a good prognosis by the Third International Workshop on Chromosomes in Leukemia.' In contrast to that report, in our study the presenting clinical and laboratory features and the treatment outcomes in children with 6q abnormalities were not significantly different from those of children lacking 6q abnormalities (P = .98). The apparent discrepancy in the prognostic significance of 6q abnormalities could be related to differences in therapy used.
Is a tumor suppressor gene involved in 6q deletion? Recently, Diaz et a13' studied 21 leukemic cell lines by Southern blot and dot blot analysis and found homozygous deletions of a-and p-interferon genes in region 9p21-22 in six cases and hemizygous deletions in three. There have been no reports of molecular analysis of homozygous or hemizygous deletion in ALL cases with 6q, however. Barletta et a136 have reported that six cell lines with del(6q) retained both copies of the c-myb protooncogene and expressed higher levels of c-myb messenger RNA, indicating possible structural and functional alterations of the c-myb locus. Ohyashiki et al,37 however, described no association of c-myb with del(6q) in two T-cell lines with a del(6q). Molecular studies are underway to clarify the region encompassing 6q21, the chromosomal region that appears to be uniformly deleted in cases with del(6q).
